Via practica 5/2009
Overview of results in selected pharmacoeconomic study of betablocker bisoprolol
Heart Failure poses an enormous financial burden. Efficient resource allocation for its management is societal and governmental challenge. In order to make informed decisions and allocate resources for HF care effectively, detailed data regarding costs for pharmacological and non-pharmacological interventions are needed. Pharmacoeconomic analysis with betablockers is one of them. Cost-effectiveness analysis of bisoprolol therapy versus placebo was performed on conditions of Swedish healthcare system.
Keywords: bisoprolol, heart failure, cost-effectiveness, CIBIS-II
